Uncomplicated Nausea and Vomiting in the Emergency Department

Overview

Nausea and vomiting is a common complaint in the emergency department. Treatment is important for many reasons. In addition to patient comfort, there are adverse effects secondary to vomiting such as dehydration, metabolic alkalosis, Mallory-Weiss tears, and aspiration. Two mediations common used for nausea in ED patients include Ondanesetron and Metoclopramide.

Full Title of Study: “Ondansetron 4 mg vs. 2 mg vs. Metoclopramide 10 mg for Nausea and Vomiting in the Emergency Department: A Randomized, Double-Blind Clinical Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Care Provider)
  • Study Primary Completion Date: December 2006

Detailed Description

This study will compare Ondansetron 4 mg vs 2 mg vs Metoclopramide 10 mg to look for efficacy in nausea and vomiting treatment for patients in the ED with many different causes. We will also look for cost effectiveness as well, since Metoclopramide is much less expensive than Ondansetron, which is less expensive at lower doses. There is little research about nausea medication in the ED literature even though these medications are used frequently in the ED for many causes of nausea.

Interventions

  • Drug: Ondansetron
    • dosage
  • Drug: Ondansetron
    • 4 mg
  • Drug: Metoclopramide
    • 10 mg IV

Arms, Groups and Cohorts

  • Active Comparator: 1
  • Active Comparator: 2
  • Active Comparator: 3

Clinical Trial Outcome Measures

Primary Measures

  • To delineate whether a high vs low dose of Ondansetron in better as opposed to an alternate medication — Metoclopramide in the ED setting for uncomplicated nausea and vomiting.
    • Time Frame: 30 minutes

Participating in This Clinical Trial

Inclusion Criteria

  • 18 years or older with nausea and at least 1 episode vomiting in the last 12 hours presenting to the York Hospital Emergency Department Exclusion Criteria:

  • Patients known to have hypersensitivity to the drugs ondansetron or metoclopramide – gastrointestinal hemorrhage, mechanical obstruction or perforation – patients with pheochromocytoma – seizure disorder – patients receiving other drugs which are likely to cause extrapyramidal reactions such as butapherones and phenothiazines – patients experiencing hyperemesis gravidum – patients unable to understand the informed consent (intoxicated, Spanish speaking) – prior antiemetics within 12 hours – inability to perform visual analog scale – renal dialysis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • WellSpan Health
  • Provider of Information About this Clinical Study
    • Marc Pollack, MD, PhD, York Hospital Emergency Medicine Physician
  • Overall Official(s)
    • Marc Pollack, MD, PhD, Principal Investigator, York Hospital Emergency Department Physician

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.